Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (currently amended) A method for inhibiting ~~and preventing~~ a malignant cell phenotype, said method comprising: administering to cells a low dose of a nitric oxide mimetic, wherein said low dose is 3 to 10,000 fold lower than a dose of said nitric oxide mimetic that produces vasodilation.

2. (original) The method of claim **1** wherein the cells are in a subject at risk for or suffering from a malignant cell phenotype.

3. (original) The method of claim **1** or **2** wherein administration of the nitric oxide mimetic inhibits metastases and development of resistance to antimalignant therapeutic modalities in the cells.

4. (original) The method of claim **1** or **2** wherein administration of the nitric oxide mimetic inhibits development of a more aggressive malignant cell phenotype in the cells upon administration of an anti-VEGF agent.

5. (original) The method of claim **1** or **2** wherein administration of the nitric oxide mimetic inhibits development of a malignant cell phenotype in cells exposed to factors which lower cellular nitric oxide mimetic activity.

6-7. (canceled)

8. (currently amended) A method for increasing efficacy of an antimalignant therapeutic modality against cancer cells, said method comprising: administering to ~~the~~ said cells a low dose of a nitric oxide mimetic, wherein said low dose is 3 to 10,000 fold lower than a dose of said nitric oxide mimetic that produces vasodilation.

9-12. (canceled)

13. (currently amended) A method for inhibiting ~~**and preventing**~~ a malignant cell phenotype in an animal, said method comprising: administering to ~~**an**~~ said animal in need thereof a low dose of a nitric oxide mimetic, wherein said low dose is 3 to 10,000 fold lower than a dose of said nitric oxide mimetic that produces vasodilation.

14-15. (canceled)

16. (original) The method of claim **13** wherein administration of the nitric oxide mimetic inhibits tumor metastases and development of resistance to antimalignant therapeutic modalities in cells in the animal.

17. (original) The method of claim **13** wherein administration of the nitric oxide mimetic inhibits development of a more aggressive malignant cell phenotype in cells in the animal upon administration of an anti-VEGF agent to the animal.

18. (original) The method of claim **13** wherein administration of the nitric oxide mimetic inhibits development of a malignant cell phenotype in animals exposed to factors which lower cellular nitric oxide mimetic activity.

19. (currently amended) A method of treating cancer in a subject, said method comprising administering to ~~**a**~~ said subject in need thereof a low dose of a nitric oxide mimetic, wherein said low dose is 3 to 10,000 fold lower than a dose of said nitric oxide mimetic that produces vasodilation.

20-21. (canceled)

22. (original) The method of claim **19** wherein the cancer is prostate cancer.

23-29. (canceled)

30-32. (canceled)

33. (new) A method for inhibiting a malignant cell phenotype, said method comprising administering to cells a low dose of a nitric oxide mimetic, wherein said low dose is between about 10^{-14} M to about 10^{-6} M of said nitric oxide mimetic.

34. (new) The method of claim 33, wherein said low dose is between about 10^{-14} M to about 10^{-10} M of said nitric oxide mimetic.

35. (new) A method for increasing efficacy of an antimalignant therapeutic modality against cancer cells, said method comprising administering to said cells a low dose of a nitric oxide mimetic, wherein said low dose is between about 10^{-14} M to about 10^{-6} M of said nitric oxide mimetic.

36. (new) The method of claim 35, wherein said low dose is between about 10^{-14} M to about 10^{-10} M of said nitric oxide mimetic.

37. (new) A method for inhibiting a malignant cell phenotype in an animal, said method comprising administering to said animal in need thereof a low dose of a nitric oxide mimetic, wherein said low dose is between about 10^{-14} M to about 10^{-6} M of said nitric oxide mimetic.

38. (new) The method of claim 37, wherein said low dose is between about 10^{-14} M to about 10^{-10} M of said nitric oxide mimetic.

39. (new) A method for treating cancer in a subject, said method comprising administering to said subject in need thereof a low dose of a nitric oxide mimetic, wherein said low dose is between about 10^{-14} M to about 10^{-6} M of said nitric oxide mimetic.

40. (new) The method of claim 39, wherein said low dose is between about 10^{-14} M to about 10^{-10} M of said nitric oxide mimetic.